IP: How will district courts interpret the Supreme Court’s decision in <em>FTC v. Actavis</em>?
The Supreme Courts recent FTC v. Actavis, Inc. decision on reverse payment settlement agreements arising in Hatch-Waxman litigation sets the stage for federal district courts to navigate a still-uncertain landscape concerning these types of settlement agreements.
July 30, 2013 at 07:17 AM
8 minute read
The original version of this story was published on Law.com
The Supreme Court's recent FTC v. Actavis, Inc. decision on reverse payment settlement agreements arising in Hatch-Waxman litigation sets the stage for federal district courts to navigate a still-uncertain landscape concerning these types of settlement agreements. This shifting landscape represents significant risk for innovator drug manufacturers unless and until the lower courts clarify the analytical framework.
The Supreme Court ultimately rejected the patent-friendly “scope of the patent” test, originally formulated by the 11th Circuit, which rendered reverse payments legal and immune from antitrust liability absent sham litigation or fraud. In its place, the Supreme Court adopted the “rule of reason,” rather than applying the more restrictive “quick look” approach urged by the Federal Trade Commission (FTC). However, the court left open the possibility that lower courts may not have to engage in a complete rule of reason analysis, particularly where there is a “large and unjustified” payment. Under those circumstances, according to the Supreme Court, the lower courts may be able to shorten their analysis and find an antitrust violation without analyzing the validity of the patent at issue. It is this removal of the patent from the antitrust analysis that presents the greatest risk for innovator companies that find themselves subject to antitrust allegations arising from a reverse payment settlement agreement. By their nature, these types of settlement agreements are usually concluded prior to a formal ruling by the district court regarding infringement and validity of the patent at issue, but the patent itself is naturally a prominent factor in the decision to settle ongoing litigation.
Counterbalancing the court's willingness to remove the patent at issue from the analysis is the court's acknowledgement that “offsetting or redeeming virtues are sometimes present” in reverse payment settlement agreements. In particular, the court identified at least three types of agreements that it suggested may not be anti-competitive. First, the court suggested that agreements to allow a generic manufacturer to enter the market prior to the patent's expiration without payment would be allowable because it would increase competition to the benefit of the consumer. Second, the court suggested that payments representing “avoided litigation costs” would also be allowable. Third, the court suggested its approval of payments that amounted to “compensation for other services the generic has promised to perform, such as distributing the patented item or helping to develop a market for that item” (i.e., “fair value for services”). With respect to the second two scenarios, the court acknowledged that these types of payments “reflect traditional settlement considerations,” and further suggested that there may be “some other justification[s]” that would render other, unidentified circumstances permissible. The court's opinion, however, does not attempt to elaborate on what these other justifications may be, leaving the remainder of the analysis to the district courts.
The dissenting opinion, written by Chief Justice Roberts, cited a study in which the typical Hatch-Waxman Act litigation cost $10 million per suit, and accused the majority of introducing a framework that would discourage settlement from these litigations. The dissent argues that the “scope of the patent” test should have been adopted. Unfortunately, by focusing on the anti-patent aspects of the majority opinion, rather than anywhere interpreting the majority opinion in a way favorable toward settlement, the dissent missed a potential opportunity to help smooth out the majority opinion and aid patent litigants.
The combination of the majority's adoption of an ill-defined “rule of reason” analysis and the dissenting opinion's recounting of the risks to that approach leave the district courts with little insight as to the proper boundaries for analyzing reverse payment settlement agreements. In the meantime, we would not be surprised to see the FTC continue its Ahab-like quest to eradicate these kinds of settlements. Innovator drug manufacturers, therefore, need to continue proceeding with caution when considering settlement of Hatch-Waxman Act litigation and particularly settlements involving reverse payments. In light of the tremendous imbalance in risk and economics between innovator and generic drug manufacturers, and the expense of Hatch-Waxman litigation, settlements are likely to remain complicated to achieve. It will be important to watch the lower court's interpretations of the Supreme Court's ruling. Whether the Supreme Court's ruling will ultimately benefit the consumer public remains to be seen.
The Supreme Court's recent FTC v.
The Supreme Court ultimately rejected the patent-friendly “scope of the patent” test, originally formulated by the 11th Circuit, which rendered reverse payments legal and immune from antitrust liability absent sham litigation or fraud. In its place, the Supreme Court adopted the “rule of reason,” rather than applying the more restrictive “quick look” approach urged by the Federal Trade Commission (FTC). However, the court left open the possibility that lower courts may not have to engage in a complete rule of reason analysis, particularly where there is a “large and unjustified” payment. Under those circumstances, according to the Supreme Court, the lower courts may be able to shorten their analysis and find an antitrust violation without analyzing the validity of the patent at issue. It is this removal of the patent from the antitrust analysis that presents the greatest risk for innovator companies that find themselves subject to antitrust allegations arising from a reverse payment settlement agreement. By their nature, these types of settlement agreements are usually concluded prior to a formal ruling by the district court regarding infringement and validity of the patent at issue, but the patent itself is naturally a prominent factor in the decision to settle ongoing litigation.
Counterbalancing the court's willingness to remove the patent at issue from the analysis is the court's acknowledgement that “offsetting or redeeming virtues are sometimes present” in reverse payment settlement agreements. In particular, the court identified at least three types of agreements that it suggested may not be anti-competitive. First, the court suggested that agreements to allow a generic manufacturer to enter the market prior to the patent's expiration without payment would be allowable because it would increase competition to the benefit of the consumer. Second, the court suggested that payments representing “avoided litigation costs” would also be allowable. Third, the court suggested its approval of payments that amounted to “compensation for other services the generic has promised to perform, such as distributing the patented item or helping to develop a market for that item” (i.e., “fair value for services”). With respect to the second two scenarios, the court acknowledged that these types of payments “reflect traditional settlement considerations,” and further suggested that there may be “some other justification[s]” that would render other, unidentified circumstances permissible. The court's opinion, however, does not attempt to elaborate on what these other justifications may be, leaving the remainder of the analysis to the district courts.
The dissenting opinion, written by Chief Justice Roberts, cited a study in which the typical Hatch-Waxman Act litigation cost $10 million per suit, and accused the majority of introducing a framework that would discourage settlement from these litigations. The dissent argues that the “scope of the patent” test should have been adopted. Unfortunately, by focusing on the anti-patent aspects of the majority opinion, rather than anywhere interpreting the majority opinion in a way favorable toward settlement, the dissent missed a potential opportunity to help smooth out the majority opinion and aid patent litigants.
The combination of the majority's adoption of an ill-defined “rule of reason” analysis and the dissenting opinion's recounting of the risks to that approach leave the district courts with little insight as to the proper boundaries for analyzing reverse payment settlement agreements. In the meantime, we would not be surprised to see the FTC continue its Ahab-like quest to eradicate these kinds of settlements. Innovator drug manufacturers, therefore, need to continue proceeding with caution when considering settlement of Hatch-Waxman Act litigation and particularly settlements involving reverse payments. In light of the tremendous imbalance in risk and economics between innovator and generic drug manufacturers, and the expense of Hatch-Waxman litigation, settlements are likely to remain complicated to achieve. It will be important to watch the lower court's interpretations of the Supreme Court's ruling. Whether the Supreme Court's ruling will ultimately benefit the consumer public remains to be seen.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View All'Utterly Bewildering': GCs Struggle to Grasp Scattershot Nature of Law Firm Rate Hikes
Regulators Say AI Enforcement Sweeps Are Reining in Hucksters, Not Innovation
Target's Don Liu: 4 Fortune 500 GC Posts, a Singular Focus on Opening Doors for Asian Americans
9 minute readTrending Stories
- 1The Law Firm Disrupted: Playing the Talent Game to Win
- 2Preparing Your Law Firm for 2025: Smart Ways to Embrace AI & Other Technologies
- 3GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
- 4BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 5Monsanto Moves to Pause PCB Trial That Starts This Week
Who Got The Work
Blank Rome partner Andrew T. Hambelton has stepped in to defend Fragrancenet.com in a pending trademark infringement lawsuit. The case, filed Aug. 29 in New York Southern District Court by the Blakely Law Group, targets the defendants for allegedly selling counterfeit fragrance products. The case, assigned to U.S. District Judge Lorna G. Schofield, is 1:24-cv-06521, Abercrombie & Fitch Trading Co. v. Quester (US) Enterprises, Inc. et al.
Who Got The Work
Davis Polk & Wardwell partners Mari Grace and Edmund Polubinski III have entered appearances for Australia-based Bitcoin-mining company Iris Energy and other defendants in a pending securities class action. The action, filed Oct. 7 in New York Eastern District Court by the Rosen Law Firm, contends that the defendants concealed the inadequacy of the company's site in Childress County, Texas, including it being 'ill-equipped' and unable to operate the company's proprietary design. The case, assigned to U.S. District Judge Peggy Kuo, is 1:24-cv-07046, Williams-Israel v. Iris Energy Limited et al.
Who Got The Work
Ryan S. Stippich of Reinhart Boerner Van Deuren has entered an appearance for biopharmaceutical company Veru Inc. and other defendants in a pending shareholder derivative lawsuit. The action, filed Sept. 30 in Wisconsin Western District Court by the Brown Law Firm on behalf of June Ovadias, accuses the defendant of failing to disclose that small sample sizes and other issues rendered it unlikely that the FDA would grant Emergency Use Authorization for the cancer drug candidate sabizabulin as a potential treatment for COVID-19. The case, assigned to U.S. District Judge William M. Conley, is 3:24-cv-00676, Ovadias, June v. Steiner, Mitchell et al.
Who Got The Work
Holland & Knight partners Cynthia A. Gierhart and Thomas Willcox Brooke have entered appearances for Pakistani American Political Action Committee and Rao Kamran Ali in a pending trademark infringement lawsuit. The action, filed Sept. 24 in District of Columbia District Court by Jackson Walker on behalf of Pakistani American Public Affairs Committee, accuses the defendants of using a mark that's confusingly similar to the plaintiff's 'Pak-Pac' marks without authorization. The case, assigned to U.S. District Judge Randolph D. Moss, is 1:24-cv-02727, Pakistani American Public Affairs Committee v. Pakistani American Political Action Committee et al.
Who Got The Work
Lauren M. Rosenberg and Yonatan Even of Cravath, Swaine & Moore have stepped in to represent Israel-based Oddity Tech Ltd. in a pending securities class action. The case, filed Aug. 30 in New York Southern District Court by Pomerantz LLP and Holzer & Holzer, contends that the defendant made materially misleading statements regarding the capability of Oddity's AI technology and ongoing civil litigation, resulting in the artifical inflation of the market price of Oddity's securities. The case, assigned to U.S. District Judge Margaret M. Garnett, is 1:24-cv-06571, Hoare v. Oddity Tech Ltd. et al.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250